{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:23:15Z","timestamp":1792531395347,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2024A04J3631"],"award-info":[{"award-number":["2024A04J3631"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22477031"],"award-info":[{"award-number":["22477031"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jconrel.2026.114934","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:51:03Z","timestamp":1776282663000},"page":"114934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Albumin-bound alkylated resiquimod for enhanced cancer immunotherapy"],"prefix":"10.1016","volume":"395","author":[{"given":"Zhang-Na","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-He","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Ge","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Zhi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114934_bb0005","doi-asserted-by":"crossref","first-page":"19961","DOI":"10.1021\/acsnano.3c05011","article-title":"Engineered selenium\/human serum albumin nanoparticles for efficient targeted treatment of parkinsons disease via oral gavage","volume":"17","author":"Xu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114934_bb0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing albumin as a carrier for cancer therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114934_bb0015","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1038\/s41467-023-42399-9","article-title":"NIR-dye bridged human serum albumin reassemblies for effective photothermal therapy of tumor","volume":"14","author":"Shi","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114934_bb0020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jconrel.2025.01.035","article-title":"Albumin-based delivery systems: recent advances, challenges, and opportunities","volume":"380","author":"Murphy","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114934_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.746646","article-title":"Recent advancements in serum albumin-based nanovehicles toward potential cancer diagnosis and therapy","volume":"9","author":"Shen","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.jconrel.2026.114934_bb0030","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.2147\/IJN.S467876","article-title":"Albumin nanoparticle-based drug delivery systems","volume":"19","author":"Qu","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114934_bb0035","doi-asserted-by":"crossref","first-page":"10557","DOI":"10.1002\/adma.201600038","article-title":"Albumin carriers for cancer theranostics: a conventional platform with new promise","volume":"28","author":"Chen","year":"2016","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114934_bb0040","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jconrel.2022.11.034","article-title":"Albumin-hitchhiking: fostering the pharmacokinetics and anticancer therapeutics","volume":"353","author":"Famta","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114934_bb0045","doi-asserted-by":"crossref","first-page":"1329636","DOI":"10.3389\/fphar.2024.1329636","article-title":"GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs","volume":"15","author":"Ji","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114934_bb0050","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/bs.acr.2020.05.004","article-title":"SPARC-p53: the double agents of cancer","volume":"148","author":"Camacho","year":"2020","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114934_bb0055","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/pharmaceutics14040728","article-title":"Emerging albumin-binding anticancer drugs for tumor-targeted drug delivery: current understandings and clinical translation","volume":"14","author":"Cho","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114934_bb0060","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1111\/1759-7714.14149","article-title":"Phase I\/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer: NJLCG1402","volume":"12","author":"Eisaku","year":"2021","journal-title":"Thoracic cancer."},{"key":"10.1016\/j.jconrel.2026.114934_bb0065","first-page":"99","article-title":"Albumin-bound formulation of paclitaxel (abraxane ABI-007) in the treatment of breast cancer","volume":"4","author":"Evelina","year":"2009","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114934_bb0070","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jconrel.2020.10.030","article-title":"Serum protein-based nanoparticles for cancer diagnosis and treatment","volume":"329","author":"Iqbal","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114934_bb0075","doi-asserted-by":"crossref","first-page":"eabl3649","DOI":"10.1126\/scitranslmed.abl3649","article-title":"Albumin nanoparticle containing a PI3K\u03b3 inhibitor and paclitaxel in combination with \u03b1-PD1 induces tumor remission of breast cancer in mice","volume":"14","author":"Song","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.114934_bb0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/jid.2011.247","article-title":"Immunomodulation by imiquimod in patients with high-risk primary melanoma","volume":"132","author":"Narayan","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jconrel.2026.114934_bb0085","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/15476910903286733","article-title":"Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists","volume":"6","author":"Hamm","year":"2009","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.jconrel.2026.114934_bb0090","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1526250","article-title":"Trial watch: toll-like receptor agonists in cancer immunotherapy","volume":"7","author":"Smith","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2026.114934_bb0095","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.114934_bb0100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.114934_bb0105","article-title":"Azide-masked resiquimod activated by hypoxia for selective tumor therapy","volume":"35","author":"Sun","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114934_bb0110","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2026.114934_bb0115","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-07-1443","article-title":"First in human phase i trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer","volume":"13","author":"Dudek","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114934_bb0120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2012-05-432393","article-title":"Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma","volume":"121","author":"Dovedi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.114934_bb0125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2019.06.003","article-title":"Formulation and preclinical evaluation of a toll-like receptor 7\/8 agonist as an anti-tumoral immunomodulator","volume":"306","author":"Lu","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114934_bb0130","article-title":"Second near-infrared photothermal semiconducting polymer nanoadjuvant for enhanced cancer immunotherapy","volume":"33","author":"Li","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114934_bb0135","doi-asserted-by":"crossref","first-page":"12671","DOI":"10.1021\/acsnano.9b04207","article-title":"Lyophilizable and multifaceted toll-like receptor 7\/8 agonist-loaded nanoemulsion for the reprogramming of tumor microenvironments and enhanced cancer immunotherapy","volume":"13","author":"Kim","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114934_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101651","article-title":"Nanoparticle-enabled concurrent modulation of phagocytosis and repolarization of macrophages for enhanced cancer immunotherapy","volume":"47","author":"Zhang","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2026.114934_bb0145","article-title":"Resiquimod-induced nanovaccine (RINV) for personalized cancer immunotherapy","volume":"64","author":"Xu","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2026.114934_bb0150","article-title":"A size-switchable nanocluster remodels the immunosuppressive microenvironment of tumor and tumor-draining lymph nodes for improved cancer immunotherapy","volume":"315","author":"Tong","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.114934_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123402","article-title":"GSH-activable and cytolytic iPep-coupled immune nanoagonist for cancer synergetic therapy","volume":"322","author":"Ji","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.114934_bb0160","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1021\/acsnano.5c16882","article-title":"Alkyl chain engineering for high-brightness near-infrared-II aggregation-induced emission nanoprobes toward high-resolution in vivo bioimaging","volume":"20","author":"Ren","year":"2026","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114934_bb0165","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.immuni.2010.03.012","article-title":"Intracellular toll-like receptors","volume":"32","author":"Blasius","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.114934_bb0170","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ejca.2006.01.003","article-title":"Tumour-associated macrophages are a distinct m2 polarised population promoting tumour progression: potential targets of anti-cancer therapy","volume":"42","author":"Sica","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.114934_bb0175","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.114934_bb0180","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.114934_bb0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.canlet.2021.06.028","article-title":"PET\/CT metabolic patterns in systemic immune activation: a new perspective on the assessment of immunotherapy response and efficacy","volume":"520","author":"Jin","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2026.114934_bb0190","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral t cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.114934_bb0195","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.114934_bb0200","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.immuni.2022.07.010","article-title":"The lung fibroblast as \u201csoil fertilizer\u201d in breast cancer metastasis","volume":"55","author":"Houthuijzen","year":"2022","journal-title":"Immunity"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:21:29Z","timestamp":1781256089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926003378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"alternative-id":["S0168365926003378"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114934","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Albumin-bound alkylated resiquimod for enhanced cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114934"}}